{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T22:46:09Z","timestamp":1745361969014,"version":"3.37.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002647","name":"Sungkyunkwan University","doi-asserted-by":"publisher","award":["2017"],"award-info":[{"award-number":["2017"]}],"id":[{"id":"10.13039\/501100002647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10147-020-01795-7","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T02:02:37Z","timestamp":1603332157000},"page":"34-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4779-6555","authenticated-orcid":false,"given":"Hyun Jin","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyon","family":"Rhew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Hyuk","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"1795_CR1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ageing\/afq057","volume":"39","author":"LC Logan","year":"2010","unstructured":"Logan LC, Sumukadas D, Witham MD (2010) Gastric acid suppressants\u2014too much of a good thing? Age and Aging 39:410\u2013411","journal-title":"Age and Aging"},{"key":"1795_CR2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS et al (2015) Trends in prescription drug use among adults in the United States from 1999\u20132012. JAMA 314:1818\u20131831","journal-title":"JAMA"},{"key":"1795_CR3","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2146\/ajhp160205","volume":"73","author":"GT Schumock","year":"2016","unstructured":"Schumock GT, Li EC, Suda KJ et al (2016) National trends in prescription drug expenditures and projections for 2016. Am J Health Syst Pharm 73:1058\u20131075","journal-title":"Am J Health Syst Pharm"},{"key":"1795_CR4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ncp.10181","volume":"33","author":"A Singh","year":"2018","unstructured":"Singh A, Cresci GA, Kirby DF (2018) Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome. Nutr Clin Pract 33:614\u2013624","journal-title":"Nutr Clin Pract"},{"key":"1795_CR5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mayocp.2017.10.022","volume":"93","author":"AK Nehra","year":"2018","unstructured":"Nehra AK, Alexander JA, Loftus CG et al (2018) Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc 93:240\u2013246","journal-title":"Mayo Clin Proc"},{"key":"1795_CR6","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001198","volume":"30","author":"MM Islam","year":"2018","unstructured":"Islam MM, Poly TN, Walther BA et al (2018) Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 30:1395\u20131405","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1795_CR7","first-page":"100","volume":"113","author":"P Laoveeravat","year":"2020","unstructured":"Laoveeravat P, Thavaraputta S, Vutthikraivit W et al (2020) Proton pump inhibitors and histamine-2 receptor antagonists on the risk of pancreatic cancer: a systematic review and meta-analysis. QJM 113:100\u2013107","journal-title":"QJM"},{"key":"1795_CR8","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","volume":"7","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T et al (2017) Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 7:e015735","journal-title":"BMJ Open"},{"key":"1795_CR9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.31917","volume":"125","author":"M Sharma","year":"2019","unstructured":"Sharma M, Holmes HM, Mehta HB et al (2019) The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 125:1155\u20131162","journal-title":"Cancer"},{"key":"1795_CR10","doi-asserted-by":"crossref","first-page":"l1580","DOI":"10.1136\/bmj.l1580","volume":"365","author":"Y Xie","year":"2019","unstructured":"Xie Y, Bowe B, Yan Y et al (2019) Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 365:l1580","journal-title":"BMJ"},{"key":"1795_CR11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1078155214527145","volume":"21","author":"VH Ha","year":"2015","unstructured":"Ha VH, Ngo M, Chu MP et al (2015) Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 21:194\u2013200","journal-title":"J Oncol Pharm Pract"},{"key":"1795_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","volume":"92","author":"NR Budha","year":"2012","unstructured":"Budha NR, Frymoyer A, Smelick GS et al (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203\u2013213","journal-title":"Clin Pharmacol Ther"},{"unstructured":"Inlyta (axitinib) tablets Label: highlight of Prescribing Information (2020) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf. Accessed 12 Mar 2020","key":"1795_CR13"},{"unstructured":"Sutent (sunitinib malate) label: highlight of prescribing information (2020) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021938s033lbl.pdf. Accessed 12 Mar 2020","key":"1795_CR14"},{"unstructured":"Votrient (pazopanib) Label: highlight of prescribing information (2020) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022465s-010S-012lbl.pdf. Accessed 12 Mar 2020","key":"1795_CR15"},{"unstructured":"Nexavar (sorafenib) tablets, oral Label: highlight of prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021923s008s009lbl.pdf. Accessed 12 Mar 2020","key":"1795_CR16"},{"key":"1795_CR17","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65\u2013W94","journal-title":"Ann Intern Med"},{"unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions: The Cochrane Collaboration, version 5.1.0. 2011. https:\/\/handbook-5-1.cochrane.org\/. Assessed 2 Mar 2020","key":"1795_CR18"},{"key":"1795_CR19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408\u2013414","journal-title":"J Clin Epidemiol"},{"key":"1795_CR20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"1795_CR21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith DG, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1795_CR22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"1795_CR23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","volume":"3","author":"MP Chu","year":"2017","unstructured":"Chu MP, Hecht JR, Slamon D et al (2017) Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC Randomized Clinical Trial. JAMA Oncol 3:767\u2013773","journal-title":"JAMA Oncol"},{"key":"1795_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5230\/jgc.2017.17.e15","volume":"17","author":"YI Kim","year":"2017","unstructured":"Kim YI, Kim MJ, Park SR et al (2017) Effect of a proton pump inhibitor on tumor bleeding prevention in unresectable gastric cancer patients: a double-blind, randomized, placebo-controlled trial. J Gastric Cancer 17:120\u2013131","journal-title":"J Gastric Cancer"},{"key":"1795_CR25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/sj.bjc.6690457","volume":"81","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Dunn JA, Whiting JL et al (1999) Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group. Br J Cancer 81:1356\u20131362","journal-title":"Br J Cancer"},{"key":"1795_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/gut.42.1.17","volume":"42","author":"JN Primrose","year":"1998","unstructured":"Primrose JN, Miller GV, Preston SR et al (1998) A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. Gut 42:17\u201319","journal-title":"Gut"},{"key":"1795_CR27","first-page":"990","volume":"2","author":"H T\u00f8nnesen","year":"1998","unstructured":"T\u00f8nnesen H, Knigge U, B\u00fclow S et al (1998) Effect of cimetidine on survival after gastric cancer. Lancet 2:990\u2013992","journal-title":"Lancet"},{"key":"1795_CR28","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1097\/MJT.0000000000000547","volume":"25","author":"AH Ali","year":"2018","unstructured":"Ali AH, Hale L, Yalamanchili B et al (2018) The effect of perioperative cimetidine administration on time to colorectal cancer recurrence. Am J Ther 25:e405\u2013e411","journal-title":"Am J Ther"},{"key":"1795_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0748-7983(95)97083-5","volume":"21","author":"M Links","year":"1995","unstructured":"Links M, Clingan PR, Phadke K et al (1995) A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol 21:523\u2013525","journal-title":"Eur J Surg Oncol"},{"key":"1795_CR30","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1177\/1078155218818237","volume":"25","author":"HE Rhinehart","year":"2019","unstructured":"Rhinehart HE, Phillips MA, Wade N et al (2019) Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. J Oncol Pharm Pract 25:1839\u20131845","journal-title":"J Oncol Pharm Pract"},{"key":"1795_CR31","doi-asserted-by":"crossref","first-page":"58801","DOI":"10.18632\/oncotarget.18522","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Liu C, Wang J et al (2017) Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget 8:58801\u201358808","journal-title":"Oncotarget"},{"key":"1795_CR32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clcc.2018.11.001","volume":"18","author":"GG Wong","year":"2019","unstructured":"Wong GG, Ha V, Chu MP et al (2019) Effects of proton pump inhibitors on FOLFOX and CapeOx regiments in colorectal cancer. Clin Colorectal Cancer 18:72\u201379","journal-title":"Clin Colorectal Cancer"},{"key":"1795_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canep.2016.12.006","volume":"46","author":"MD Kearns","year":"2017","unstructured":"Kearns MD, Voursi B, Yang YX (2017) Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol 46:80\u201384","journal-title":"Cancer Epidemiol"},{"key":"1795_CR34","doi-asserted-by":"crossref","first-page":"85542","DOI":"10.18632\/oncotarget.13458","volume":"7","author":"NB Kumarakulasinghe","year":"2016","unstructured":"Kumarakulasinghe NB, Syn N, Soon YY et al (2016) EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget 7:85542\u201385550","journal-title":"Oncotarget"},{"key":"1795_CR35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-016-3087-6","volume":"78","author":"LH Lam","year":"2016","unstructured":"Lam LH, Capparelli EV, Kurzrock R (2016) Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 78:427\u2013432","journal-title":"Cancer Chemother Pharmacol"},{"key":"1795_CR36","first-page":"647","volume":"23","author":"M Nieves Sedano","year":"2018","unstructured":"Nieves Sedano M, Manuel Caro Teller J, Garc\u00eda Mu\u00f1oz C et al (2018) Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. J BUON 23:647\u2013653","journal-title":"J BUON"},{"key":"1795_CR37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cllc.2016.01.006","volume":"17","author":"Y Zenke","year":"2016","unstructured":"Zenke Y, Yoh K, Matsumoto S et al (2016) Clinical impact of gastric acid-suppression medication use on the Efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer 17:412\u2013418","journal-title":"Clin Lung Cancer"},{"key":"1795_CR38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0019-509X.19203","volume":"42","author":"R Parshad","year":"2005","unstructured":"Parshad R, Hazrah P, Kumar S et al (2005) Effect of preoperative short course famotidine on TILs and survival in breast cancer. Indian J Cancer 42:185\u2013190","journal-title":"Indian J Cancer"},{"key":"1795_CR39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13046-015-0194-x","volume":"34","author":"BY Wang","year":"2015","unstructured":"Wang BY, Zhang J, Wang JL et al (2015) Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 34:85","journal-title":"J Exp Clin Cancer Res"},{"key":"1795_CR40","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1345\/aph.1P225","volume":"44","author":"SV Keisner","year":"2010","unstructured":"Keisner SV, Shah SR, Jean GW et al (2010) Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer. Ann Pharmacother 44:1538\u20131544","journal-title":"Ann Pharmacother"},{"key":"1795_CR41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clgc.2017.05.019","volume":"15","author":"AA Lalani","year":"2017","unstructured":"Lalani AA, McKay RR, Lin X et al (2017) Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15:724\u2013732","journal-title":"Clin Genitourin Cancer"},{"key":"1795_CR42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.2017-0578","volume":"23","author":"RK McAlister","year":"2018","unstructured":"McAlister RK, Aston J, Pollack M et al (2018) Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist 23:686\u2013692","journal-title":"Oncologist"},{"key":"1795_CR43","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/ijc.31204","volume":"142","author":"M Nayan","year":"2018","unstructured":"Nayan M, Juurlink DN, Austin PC et al (2018) Medication use and kidney cancer survival: A population-based study. Int J Cancer 142:1776\u20131785","journal-title":"Int J Cancer"},{"key":"1795_CR44","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","volume":"25","author":"O Mir","year":"2019","unstructured":"Mir O, Touati N, Lia M et al (2019) Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 Trials. Clin Cancer Res 25:1479\u20131485","journal-title":"Clin Cancer Res"},{"key":"1795_CR45","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1940-6207.CAPR-14-0002","volume":"7","author":"S Papagerakis","year":"2014","unstructured":"Papagerakis S, Bellile E, Peterson LA et al (2014) Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila) 7:1258\u20131269","journal-title":"Cancer Prev Res (Phila)"},{"key":"1795_CR46","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1039\/C6BM00504G","volume":"4","author":"N Peng","year":"2016","unstructured":"Peng N, Wu B, Wang L et al (2016) High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy. Biomater Sci 4:1802\u20131813","journal-title":"Biomater Sci"},{"key":"1795_CR47","first-page":"20664","volume":"8","author":"W Han","year":"2015","unstructured":"Han W, Hou G, Liu L (2015) Polyphyllin I (PPI) increased the sensitivity of hepatocellular carcinoma HepG2 cells to chemotherapy. Int J Clin Exp Med 8:20664\u201320669","journal-title":"Int J Clin Exp Med"},{"key":"1795_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-014-0073-x","volume":"33","author":"K Lindner","year":"2014","unstructured":"Lindner K, Borchardt C, Sch\u00f6pp M et al (2014) Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res 33:73","journal-title":"J Exp Clin Cancer Res"},{"key":"1795_CR49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drup.2015.08.004","volume":"23","author":"S Taylor","year":"2015","unstructured":"Taylor S, Spugnini EP, Assaraf YG et al (2015) Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat 23:69\u201378","journal-title":"Drug Resist Updat"},{"key":"1795_CR50","first-page":"2669","volume":"5","author":"HL McLeod","year":"1999","unstructured":"McLeod HL, Evans WE (1999) Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 5:2669\u20132671","journal-title":"Clin Cancer Res"},{"key":"1795_CR51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","volume":"50","author":"P Di Gion","year":"2011","unstructured":"Di Gion P, Kanefendt F, Jaehde U et al (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551\u2013603","journal-title":"Clin Pharmacokinet"},{"unstructured":"Tarceva (erlotinib) Label (2020) Highlights of Prescribing Information: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021743s14s16lbl.pdf. Accessed 30 Mar 2020","key":"1795_CR52"},{"key":"1795_CR53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CAD.0000000000000212","volume":"26","author":"H Kletzl","year":"2015","unstructured":"Kletzl H, Giraudon M, Ducray PS et al (2015) Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs 26:565\u2013572","journal-title":"Anticancer Drugs"},{"key":"1795_CR54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/gast.1996.v110.pm8612992","volume":"110","author":"M Feldman","year":"1996","unstructured":"Feldman M, Cryer B, McArthur KE et al (1996) Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 110:1043\u20131052","journal-title":"Gastroenterology"},{"key":"1795_CR55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1997.03550080069041","volume":"278","author":"A Hurwitz","year":"1997","unstructured":"Hurwitz A, Brady DA, Schaal SE et al (1997) Gastric acidity in older adults. JAMA 278:659\u2013662","journal-title":"JAMA"},{"key":"1795_CR56","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3892\/ol.2013.1566","volume":"6","author":"F Tas","year":"2013","unstructured":"Tas F, Ciftci R, Kilic L et al (2013) Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett 6:1507\u20131513","journal-title":"Oncol Lett"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01795-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T06:36:49Z","timestamp":1723790209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01795-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"26 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HJS, KR, YJL, and IHH declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}